阿舒瑞韋

阿舒瑞韋
	IUPAC名; 3-Methyl-N[(2-methyl-2-propanyl)oxy]carbonylL-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-N(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropylL-prolinamide
	系統名; tert-Butyl {(2S)-1-[(32S,34R,61R,62S)-17-chloro-62-ethenyl-14-methoxy-4,7,9,9-tetraoxo-2-oxa-9λ6-thia-5,8-diaza-1(1)-isoquinolina-3(4,2)-pyrrolidina-6(1,1),10(1)-dicyclopropadecaphan-31-yl]-3,3-dimethyl-1-oxobutan-2-yl}carbamate
別名	BMS-650032
識別
CAS號	630420-16-5
PubChem	16076883
ChemSpider	17235944
SMILES	O=C(N5[C@H](C(=O)N[C@@]2(C(=O)NS(=O)(=O)C1CC1)[C@H](\C=C)C2)C[C@@H](Oc3ncc(OC)c4c3cc(Cl)cc4)C5)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C;
InChI	1/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1;
InChIKey	XRWSZZJLZRKHHD-WVWIJVSJBJ
ChEBI	134723
DrugBank	DB11586
KEGG	D10093
IUPHAR配體	10882
性質
化學式	C35H46ClN5O9S
摩爾質量	748.29 g·mol−1
藥理學
ATC代碼	J05AP06（J05）
藥品分級
	若非註明，所有數據均出自標準狀態（25 ℃，100 kPa）下。

阿舒瑞韋（INN：Asunaprevir；開發代號：BMS-650032），在日本和俄羅斯的商品名為Sunvepra，^[2]是一種治療C型肝炎的實驗性候選藥物，由百時美施貴寶公司開發，已於2013年完成III期臨床試驗。^[3]

阿舒瑞韋是C型肝炎病毒絲氨酸蛋白酶NS3的抑制劑。^[4]阿舒瑞韋與聚乙二醇干擾素和利巴韋林的藥物組合正在進行測試，以及與其他直接作用抗病毒藥物（包括達拉他韋）在無干擾素方案中的聯合測試。^[5]^[6]^[7]

參考資料

^ Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. （原始內容存檔於2023-04-10）.
^ Sunvepra (asunaprevir) soft gelatin capsules 100 mg. Registration certificate. State Register of Medicines. [26 August 2015]. （原始內容存檔於2016-03-04）（Russian）.
^ A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients. ClinicalTrials.gov. 23 September 2015 [2024-03-03]. （原始內容存檔於2014-07-14）.
^ C. Reviriego. Asunaprevir. HCV serine protein NS3 inhibitor, Treatment of hepatitis C virus. Drugs of the Future. 2012, 37 (4): 247–254 [2024-03-03]. doi:10.1358/dof.2012.037.04.1789350. （原始內容存檔於2018-06-03）.
^ Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. The New England Journal of Medicine. January 2012, 366 (3): 216–24. PMID 22256805. doi:10.1056/NEJMoa1104430 .
^ Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study. Bloomberg. Apr 19, 2012 [2024-03-03]. （原始內容存檔於2014-01-18）.
^ AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders 網際網路檔案館的存檔，存檔日期2015-02-08.. Highleyman, L. HIVandHepatitis.com. 8 November 2011.

[1] Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. （原始內容存檔於2023-04-10）.

[2] Sunvepra (asunaprevir) soft gelatin capsules 100 mg. Registration certificate. State Register of Medicines. [26 August 2015]. （原始內容存檔於2016-03-04）（Russian）.

[3] A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients. ClinicalTrials.gov. 23 September 2015 [2024-03-03]. （原始內容存檔於2014-07-14）.

[4] C. Reviriego. Asunaprevir. HCV serine protein NS3 inhibitor, Treatment of hepatitis C virus. Drugs of the Future. 2012, 37 (4): 247–254 [2024-03-03]. doi:10.1358/dof.2012.037.04.1789350. （原始內容存檔於2018-06-03）.

[5] Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. The New England Journal of Medicine. January 2012, 366 (3): 216–24. PMID 22256805. doi:10.1056/NEJMoa1104430 .

[6] Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study. Bloomberg. Apr 19, 2012 [2024-03-03]. （原始內容存檔於2014-01-18）.

[7] AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders 網際網路檔案館的存檔，存檔日期2015-02-08.. Highleyman, L. HIVandHepatitis.com. 8 November 2011.

[2]

[3]

[4]

[5]

[6]

[7]